The alphavirus Chikungunya virus is transmitted to humans via infected mosquitos. Most infected humans experience symptoms which can range from short-term fatigue and fever to debilitating arthritis that can last for months or years. Some patients relapse and experience symptoms months or years after the initial bout of disease. The capsid protein of Chikungunya virus forms a shell around the viral RNA genome; this structure is called the nucleocapsid core.
55 56
Introduction
Chikungunya virus (CHIKV) is a re-emerging alphavirus that is spread by a mosquito vector to humans and other vertebrates (1, 2). An estimated 3 million people are affected annually by CHIKV and approximately 80-95% develop symptoms 2 to 12 days after being bitten by an infected mosquito (1, 3, 4) . Infected individuals typically suffer from short-term fever, fatigue, and joint pain; however, approximately 25-48% develop long-term debilitating arthritis that can persist for months or years (2, 5, 6) . Previously, CHIKV outbreaks were limited to tropical and subtropical Asia and Africa, but outbreaks have now been reported in Europe, North America, South America, and the Caribbean (2) . This expansion is due in part to a mutation in a viral protein, which supportstransmission of the virus in both the Aedes aegypti and Aedes albopictus mosquito vectors (7) . A number of inhibitors of CHIKV have been identified including compounds that target the virus lifecycle including genome replication, viral protein synthesis, and virus egress, specifically the interaction of the core with the viral spikes (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) . These compounds, however, are effective only at high concentrations or resistance is easily acquired. Antiviral compounds that target host factors required by CHIKV reduce viral titers but these compounds are by definition affecting normal cellular function (10, (20) (21) (22) .
Antivirals that target the functions of capsid proteins of approximately half a dozen other eukaryotic viruses have been successful direct acting antivirals. While the core is modulated in all the inhibitors identified, their mode of action and lifecycle stage varies. Work with polio and dengue viruses (23, 24) show the that when antivirals (V-073 for polio and ST-148 for dengue) target the capsid/core proteins, the virus is less likely to develop drug resistance because the viral capsids/cores will contain both drug-susceptible and drug-resistant capsid proteins. Because of this chimera oligomer, the drug is still effective despite mutations arising. Additional studies 169  170  171  172  173  174  175  176  177  178  179  180  181  182  183  184  185  186  187  188  189  190  191  192  193  194  195  196  197  198  199  200  201  202  203  204  205  206  207  208  209  210  211  212  213  214  215  216  217  218  219  220  221  222  223  224 have shown that ST-148, is thought to make the dengue core more rigid by promoting capsid contacts, thus interfering with the packaging and disassembly of viral RNA (25, 26) . One could envision that a dengue core containing even a few core proteins that have stronger contacts with adjacent subunits would disrupt the overall assembly of the core. Small molecules have been identified that target Hepatitis B virus capsid assembly (27) (28) (29) (30) (31) ; heteroaryldihydropyrimidines compounds promote assembly and lead to empty or misassembled particles that have fallen into kinetic traps (27, 30) . In contrast, inhibitors of enteroviruses, such as the WIN compounds for rhinoviruses, prevent the disassembly of the capsid particle (32, 33) . Here, the two most efficient WIN compounds bind to a pocket in the capsid protein inhibiting breathing and disassembly of the capsid (33, 34) . Two groups of antivirals that target HIV capsid have been identified. Small molecules will interfere with the virion maturation by targeting the cleavage and rearrangement of capsid, which is necessary for infectious viron maturation (35) (36) (37) (38) (39) (40) (41) (42) . The second group of antivirals interfere with the capsid -capsid protein interactions, and interfere with assembly, genome packaging, and uncoating (40, 43, 44) .
CHIKV, like other Alphaviruses (Ross River virus, Venezuelan Equine Encephalitis virus,
Eastern Equine Encephalitis virus) are enveloped, positive-sense RNA viruses (45) . Particles have icosahedral symmetry and are organized with (i) an internal nucleocapsid core, consisting of the capsid protein and RNA genome, (ii) a host-derived lipid bilayer surrounding this core, and (iii) a shell of viral glycoproteins on the particle surface which are required for cell entry (46, 47) . The capsid protein consists of two domains, a disordered N-terminal domain that interacts with the viral RNA, and a C-terminal chymotrypsin-like domain that makes up of the outer surface of the core. The C-terminal domain of capsid protein interacts with the endo domain of 225  226  227  228  229  230  231  232  233  234  235  236  237  238  239  240  241  242  243  244  245  246  247  248  249  250  251  252  253  254  255  256  257  258  259  260  261  262  263  264  265  266  267  268  269  270  271  272  273  274  275  276  277  278  279  280 one of the viral glycoproteins, E2. The different roles of the capsid protein in the viral lifecycle require multiple interactions of capsid protein.
Assembly of alphavirus nucleocapsid cores can be recapitulated in vitro; these are called core-like particles (CLPs) (48) . CLPs can be assembled by mixing recombinant capsid protein with viral RNA. CLPs are also formed when non-viral cargo (e.g., single-stranded DNA and RNA oligonucleotides, polyanion small molecules, or gold particles coated with nucleic acid) are mixed with capsid protein (49) . CLPs can be encapsidated by viral glycoproteins, and the newly formed virus-like particles are able to enter and disassemble within a new cell (50, 51) . A 27mer DNA oligo interacts in a 1:1 molar ratio to neutralize the basic N-terminus of the capsid protein (52, 53) to initiate CLP assembly. CLPs are 40 nm in diameter and structurally similar to cores in virions (52) (53) (54) (55) . The efficiency of CLP assembly can be regulated by ionic strength. Low ionic strength buffers promote CLP assembly and inhibit CLP disassembly. High ionic strength buffers will inhibit CLP assembly and will promote CLP disassembly (48-50, 52-54, 56) . The need for anionic cargo and the sensitivity to ionic strength indicate that the capsid protein-capsid protein interactions during assembly are extremely weak and that assembly depends on electrostatic interaction with cargo.
In this study, we sought to identify small molecule modulators of CHIKV CLP assembly (48, 53, 57) . We monitored the fluorescence quenching of fluorophore-labelled oligonucleotides to monitor nucleic acid packaging. We screened a 10,000 compound library in vitro. From the 45 compounds identified in vitro, 12 were selected for validation in cell culture with CHIKV. We report that four compounds could block the production of infectious CHIKV particles by at least 90% in a dose-dependent manner. Furthermore, the compound that reduced titers the most ,   281  282  283  284  285  286  287  288  289  290  291  292  293  294  295  296  297  298  299  300  301  302  303  304  305  306  307  308  309  310  311  312  313  314  315  316  317  318  319  320  321  322  323  324  325  326  327  328  329  330  331  332  333  334  335  336 reduced the amount of cytoplasmic cores present in infected cells, consistent with this compound targeting the nucleocapsid core during infection.
Materials and Methods

Capsid and oligomer preparation
The capsid protein from CHIK 181/25 (58) was cloned into the pET29 vector and expressed in Rosetta2pRARE2 cells as done previously for other alphavirus capsid proteins (17, 18, 48, 54, 59) . For ease of purification, we included a 6-His tag at the N-terminus prior to the first amino acid. Cells were grown at 37°C, when the OD600 was between 0.4-0.6, 1 mM IPTG was added.
Cells were grown for an additional 4 hours. Cells were pelleted and resuspended in 20 mM sodium phosphate buffer containing 2μg/ml leupeptin, 2 μg/ml aprotinin, and 1mM PMSF to a final cell density of 0.06-0.08 g/ml (53) . Samples were lysed using a cell cracker or a sonicator, sodium chloride was added to a concentration of 500 mM, and then lysates centrifuged at in a Beckman JA17 rotor at 23000 x g or 45 minutes at 4°C. Clarified supernatant was applied to a 5ml HisTrap column (GE Lifesciences) and after washing with 5 to 10 column volumes of 20 mM sodium phosphate, pH 7.4, 500 mM NaCl, and 10 mM imidazole until A280 and A260 returned to baseline, the protein was eluted with a similar buffer but with 800 mM imidazole. For further purification, peak fractions were collected and diluted to 0.25M NaCl with 20 mM sodium phosphate, pH 7.4. Samples were applied to a HiTrap SP column (GE Lifesciences), washed with 20 mM HEPES pH 7.4, 0.25 M NaCl, 5 mM EDTA and then eluted from the column using 20 mM HEPES pH 7.4, 1.3 M NaCl, and 5 mM EDTA. Fractions with an absorbance substantially above background and an 260/280 absorbance ratios less than 0.6 were pooled, concentrated with a centricon 10K concentrator, and buffer exchanged into 20 mM HEPES and 150 mM NaCl. The resulting material served as our stock solution. Protein concentration was determined by measuring absorbance at 280 nm using an extinction coefficient of 39 670 M 1 cm 1 .
High Throughput Screen
High throughput screen assays were performed at the Chemical Genomics Core Facility at IUPUI (Indianapolis, IN). Each compound of the Chembridge 10K library (San Diego, CA; kindly provided by Assembly Biosciences) was prepared as a 1mM stock in 100% DMSO in 384-well plates. We conducted two screens by adjusting the assembly conditions. For the inhibitor screen, we used a final NaCl concentration of 320 mM to achieve approximately 75% assembly of CLPs and focused on compounds that inhibited assembly. In the second screen, we used a final NaCl concentration of 570 mM NaCl to achieve approximately 30% assembly of handler, Tecan). After a 5-10 minute incubation at room temperature to initiate compoundprotein interaction, 10 l of the 0.625 M oligomer mixture was added to a final volume of 25 l. Plates were centrifuged briefly and incubated at room temperature for 2 hours in the dark.
Finally, the fluorescence signal was recorded with an EnVision 2102 Multilabel Plate Reader (Perkin Elmer) with monochromators set to 531 nm excitation and 595 nm emission.
Each assay consisted of thirty-two 384 plates and each plate contained a series of controls.
One column (16 wells) controlled for assembly in the presence of increasing ionic strength to ensure the fluorescence signal inversely correlated to assembly. A second column had assembly reactions at the salt concentration being used in the assay (320 mM for inhibitors and 570 mM for promoters) to give a baseline fluorescence signal for 75% assembly and 30% assembly, respectively. The third and fourth columns contained reactions with maximal assembly (100 mM NaCl) and minimal assembly (800 mM) to establish the minimum and maximum fluorescence signals, respectively. Also included were capsid protein/no oligonucleotide controls.
High Throughput Data Analysis
HTS data quality was monitored using the standard curve as well as the positive and negative controls on each plate. Data points were normalized by averaging of all the data points in the same position across all plates to eliminate systematic instrumental error on specific wells. We defined potential hits in the following way to minimize random error and allow comparison of chemical structures: hits are 3 sigma (i.e. 3 standard deviations of the signal distribution) away from the average of the primary screen and 2 sigma from the average of the secondary screen.
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Tissue culture reagents
All tissue culture experiments were performed using the baby hamster kidney cell line BHK-21, here referred to as BHK cells. Cells were passaged in minimum essential medium (MEM) supplemented with non-essential amino acids, penicillin-streptomycin, and L-glutamine in 10% fetal bovine serum (Corning Cellgro, Manassas, VA) and grown at 37°C and 5% CO2.
Virus preparation and titering
The CHIK 181/25 virus used in this study was a generous gift from Dr. Terence Dermody's lab. Nanoluc was cloned into the hypervariable loop of nsP3, after amino acid 490, or after capsid, as described in the literature (61, 62) . Infectious virus was generated as described in (63) . Briefly, SacI-linearized CHIK-capsid::nLucFM2 cDNA plasmid was transcribed into infectious RNA in vitro using a synthetic cap analog and SP6 RNA polymerase (New England BioLabs, Ipswich, MA). RNA was electroporated (1500 V, 25 200 into BHK cells resuspended in phosphate-buffered saline (PBS) in a 2-mm cuvette. Upon display of significant cytopathic effect, media were harvested and clarified at 5,000 × g for 5 min.
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BHK cells (30,000 cells/well) were plated into a 96-well plate approximately 24 hours prior to adding the compounds. The supernatant was aspirated off and 100μl fresh phenol red-free complete MEM with 10% FBS was added. Then, compounds dissolved in DMSO were added to a final concentration of 10 M. Plates were incubated for 24 hours at 37°C with 5% CO2. Then, media was aspirated and we assessed ATP levels in cell lysates using the CellTiter-Glo® Luminescent Cell Viability Assay (Promega). Briefly, 30 L of cell-titer glow reagent was added to each well and, after 10 minutes, the luminescence was measured using a Synergy H1 plate reader (BioTek).
Antiviral assays
To test if compounds inhibited infectious virus production, 300,000 BHK cells/well were 561  562  563  564  565  566  567  568  569  570  571  572  573  574  575  576  577  578  579  580  581  582  583  584  585  586  587  588  589  590  591  592  593  594  595  596  597  598  599  600  601  602  603  604  605  606  607  608  609  610  611  612  613  614  615  616 2.8 qPCR to measure particle numbers At 24 hrs post infection, supernatants from infected BHK cells were collected and clarified (5000 x g for 5 min at room temperature). Virus concentration was determined by RT-qPCR using 5 μl of each supernatant as template for cDNA synthesis and the method described (64) .
Primers used were Forward: 5'ggaataaagacggatgatagc and Reverse: 5'ggtcgggaatgaaatttttcc. The absolute quantities of viral RNAs were determined using a standard curve of in vitro transcribed RNA.
Nucleocapsid core isolation from infected cells
Cytoplasmic cores from virus-infected cells were isolated as described previously (65).
Briefly, four 100 mm dishes of BHK cells were infected with CHIK at a MOI=0.1. Virus was allowed to adsorb for one hour and then cells were washed twice with PBS. To two plates, serum-free media and 1% DMSO was added, and to the other two plates, 1 M 4BSA (in DMSO) in serum-free media was added. Cells were harvested 24 hours post infection, pellets were washed with ice-cold PBS, resuspended in 1 ml of TNE buffer (10 mM TrisCl, pH 7.5 10 mM NaCl, and 20 mM EDTA). Cells were incubated on ice for 20 minutes. The nuclei were removed by spinning at 1000 x g for 10 minutes at Supernatants were loaded on 10-40% sucrose gradients in TNE+0.1% Triton X-100 buffer. Gradients were spun in SW41 rotor for 2.5 hours at 32,000 x g at 15°C. Fractions collected and analyzed by western blot (65). 617  618  619  620  621  622  623  624  625  626  627  628  629  630  631  632  633  634  635  636  637  638  639  640  641  642  643  644  645  646  647  648  649  650  651  652  653  654  655  656  657  658  659  660  661  662  663  664  665  666  667  668  669  670  671  672 We chose to identify antiviral compounds that target the CHIKV capsid protein because the capsid protein must make several crucial interactions to generate infectious virus. The core protects the viral RNA genome during virus transmission, but must dissociate under the correct physiological conditions for virus replication (46) . In addition, the properly assembled core interacts with the cytoplasmic domain of the viral glycoprotein E2 (66) suggesting the assembly of the core is critical for particle budding. In vitro assembled CLPs are structurally and functionally similar to nucleocapsid cores from infected cells (50, 51, 54) making them ideal systems for studying core assembly (48, 49, 52, 53, 59, (67) (68) (69) .
Results and Discussion
A high throughput screen to identify compounds that modulate core-like particle assembly
CLPs can be assembled in vitro by mixing equimolar ratios of capsid protein and 27mer
DNA oligomers in the presence of 100 mM NaCl, as previously demonstrated (52) interactions. We observed that the decrease in Cy3 fluorescence had a greater dynamic range than the increase in Cy5 fluorescence, thus we used the change in the Cy3 fluorescence as a read- 673  674  675  676  677  678  679  680  681  682  683  684  685  686  687  688  689  690  691  692  693  694  695  696  697  698  699  700  701  702  703  704  705  706  707  708  709  710  711  712  713  714  715  716  717  718  719  720  721  722  723  724  725  726  727  728 out for oligo packaging and CLP assembly. We found that 1.5 M capsid protein and 1.5 M total oligomer provided a strong signal to discriminate between packaged and unpackaged DNA.
This ratio still maintained the 1:1 mole ratio while reducing the concentrations of capsid protein and oligomer used.
We used this FRET-based in vitro assay (48, 53, 54, 57) to screen 10,000 compounds for their ability to affect fluorescence as a proxy for their ability to modulate CLP assembly. We anticipated the following outcomes (Figure 1 ). Compared to a control, compounds could inhibit CLP formation resulting in more free nucleotide and higher fluorescence ( Figure 1B) ; they could promote assembly in the absence or reduced amount of DNA also resulting in higher fluorescence ( Figure 1C) ; they could enhance the overall amount of assembly resulting in more oligonucleotide packaging and lower fluorescence ( Figure 1D) ; they could increase the amount of oligos packaged in a CLP, also resulting in lower fluorescence ( Figure 1E ). Our screen, without other assays, does not determine which scenario is occurring, merely that there is a change in the CLP assembly process.
To maximize our chances of identifying assembly enhancing and inhibiting compounds we screened compounds under two different ionic strength conditions. In the first screen, we used low ionic strength conditions where packaging was robust and fluorescence suppressed.
Compounds that decrease the packaging of oligomers, thereby raising the fluorescence signal from Cy3, would be readily identified ( Figures 1B and 1C) . In the second screen, we used moderate ionic strength conditions where packaging was reduced and fluorescence higher; this was used to identify compounds that decrease the fluorescence signal from Cy3, suggesting an increase in the packaging of oligomers ( Figures 1D and 1E) . 729  730  731  732  733  734  735  736  737  738  739  740  741  742  743  744  745  746  747  748  749  750  751  752  753  754  755  756  757  758  759  760  761  762  763  764  765  766  767  768  769  770  771  772  773  774  775  776  777  778  779  780  781  782  783  784 To test the core modulation properties of the compounds, CLP assembly was initiated by adding the oligomer mixture to purified capsid protein and 10 μM compound in the appropriate ionic strength buffer. In the lower ionic strength screen, we found 70 molecules out of 10,000 that resulted in an increase in Cy3 fluorescence by at least 3 standard deviations from the mean fluorescence (Figure 2A , dark blue line, +3 ). In the moderate ionic strength screen, we found 36 compounds that decreased Cy3 florescence by at least 3 standard deviations from the mean florescence ( Figure 2B , dark green line, -3 ). From our two screens we had at least 106 compounds with CLP modulating properties in vitro (Figures 2A and 2B ).
There were 19 compounds that increased fluorescence in both the low and moderate ionic strength screens ( Figure 3A ). Since the moderate ionic strength screen was not as sensitive to detecting increased fluorescence, we looked for compounds that increased fluorescence by 2 standard deviations in this screen that also increased fluorescence by 3 standard deviations in the low ionic strength. In a similar process, 26 compounds that increased fluorescence were identified in both screens ( Figure 3B ).
We determined the efficacy of the 45 putative antiviral compounds based on in vitro dose response of CLP assembly (Supplemental Figure 1) . These assays were performed using standard conditions of 1.5 M capsid protein, 1.5 oligomer, and either 320 mM or 570 mM NaCl. The AC50 (defined as half-maximal activity concentration) of the compounds ranged from 1 to 9 M. Based on efficacy, 12 compounds, six that increased fluorescence and six that decreased fluorescence, were selected for further characterization. 785  786  787  788  789  790  791  792  793  794  795  796  797  798  799  800  801  802  803  804  805  806  807  808  809  810  811  812  813  814  815  816  817  818  819  820  821  822  823  824  825  826  827  828  829  830  831  832  833  834  835  836  837  838  839  840 The screen to identify CLP assembly modulators was performed using purified components to maximize the likelihood of finding a compound that interfered with capsid protein-oligo or capsid protein-capsid protein interactions rather than an off-target cellular effect. Now we wanted to determine if the compounds identified as core modulators in vitro were also effective during viral infections in cell culture.
Production of CHIKV infectious particles is reduced with core modulating compounds
The 12 selected compounds were tested for toxicity and antiviral efficacy. To test toxicity, were detrimental to cells based on reduced levels of ATP and altered cellular morphology.
Based on these findings, we only tested the eight non-toxic compounds (4CA, 4BA, 1PA, 7AA, 4BSA, NNU, 2P, and 2CA) for their ability to inhibit infectious CHIK virus production.
We performed a series of experiments where the time at which the compounds were added was varied relative to CHIK virus adsorption: BHK cells were incubated with the compounds continuously ( Figure 5A ), only after viral absorption ( Figure 5B ), or only during viral absorption ( Figure 5C ). In all cases, supernatants from each of these experiments were collected 24 hours post virus infection and assessed for infectious virus by plaque assays. All eight of the compounds had anti-viral activity ( Figure 5 ), albeit to differing extents depending on when the compound was added during the infection. 841  842  843  844  845  846  847  848  849  850  851  852  853  854  855  856  857  858  859  860  861  862  863  864  865  866  867  868  869  870  871  872  873  874  875  876  877  878  879  880  881  882  883  884  885  886  887  888  889  890  891  892  893  894  895  896 When 10 M of compound was incubated with CHIKV-infected BHK cells continuously ( Figure 5A ), all eight compounds inhibited infectious virus production by at least 50% when compared to the DMSO-treated control cells. Compound 4BSA was the most potent inhibitor of infectious virus production and suppressed viral titer by at least 90%. When compounds were added to cells after virus absorption ( Figure 5B) , they all reduced the amount of infectious virus produced by at least 50%, except for 4CA and 5NSBA. In the final time-of-addition experiment, we treated BHK cells with compound for only 1 hour during absorption of the virus ( Figure 5C) and found that compounds 5NSBA, 1PA, and 7AA were much less effective and no longer inhibited production of infectious virus by 50%.
The eight compounds that exhibited antiviral activity were identified from the screen that only contained capsid protein and oligomer. Therefore, we hypothesized the compounds primarily interfere with an aspect of core assembly or disassembly. We cannot say if the antivirals interfere with capsid-nucleic acid, capsid protein-capsid protein, or both types of interactions. The time of addition experiments may suggest whether the compounds could affect early steps in infection (e.g. disassembly) or late steps (e. g. assembly) or at multiple steps. We hypothesize that compounds that led to higher fluorescence inhibit new core assembly and thus limit production of infectious virus. Compounds 1PA and 7AA were consistent with this idea.
They were only an effective antiviral if added continuously or after virus absorption ( Figure 5A,   5B ), and much of the antiviral activity was lost if this compound was added only during virus absorption ( Figure 5C ). Compounds 4BA and 4CA were antivirals regardless of time of addition.
Compounds that led to lower fluorescence were hypothesized to inhibit nucleocapsid core disassembly, an earlier part of the virus life cycle. Our results show 4BSA, NNU, and 2CA were effective antivirals even when added only during virus absorption ( Figure 5C ) consistent with these compounds acting during an early step of the viral life cycle. 5NBSA worked the best when added continuously, perhaps working post-disassembly.
Plaque assays reproducibly showed that eight of the compounds identified in our screen inhibited production of infectious virus (multiple independent virus preparations) ( Figure 5 ).
Many high throughput screens that identify new antiviral compounds use reporter-based assays to quickly look for a 50-75% reduction in reporter activity (8) (9) (10) (11) . We initially sought to confirm the antiviral activity of all our compounds by using luciferase reporter viruses. We inserted luciferase into either a hypervariable loop of nsP3 (nsP3:luciferase) or after capsid protein (capsid:luciferase) (61, 62) . CHIKV containing the luciferase reporter was added at an MOI=0.01 and rocked for 1 hour. Then the cells were washed and each of the eight compounds was added with fresh media. After 6 or 9 hours when using the nsP3:luciferase or capsid:luciferase virus (when maximum signal was observed), cells were lysed and luciferase activity determined. In our hands, most of the eight antiviral candidates failed to yield consistent luciferase activity results, thereby making it difficult to estimate the effect of the compounds (Supplemental Figure 2 ). Only 4BSA consistently and reproducibly inhibited the luciferase activity while the other antiviral compounds found in our screen had much wider variation. We found the reporter assay was biased towards identifying compounds that would inhibit entry and replication since time points were taken relatively early in the viral lifecycle. These data suggest that compounds that target the later stages of assembly such as core assembly, particle assembly, and have subsequent effects in particle spread, may be missed in this type of reporter screen. 953  954  955  956  957  958  959  960  961  962  963  964  965  966  967  968  969  970  971  972  973  974  975  976  977  978  979  980  981  982  983  984  985  986  987  988  989  990  991  992  993  994  995  996  997  998  999  1000  1001  1002  1003  1004  1005  1006  1007  1008 We next tested the dose-dependence inhibition of our most inhibitory compounds (4BA, 1PA, 4BSA, and NUU) to estimate their EC50 or the half-maximal effective concentration.
Efficacy of antiviral compounds in CHIKV infection
Following the addition scheme of Figure 5B , cells were treated with different concentrations of compound after virus adsorption for one hour. EC50 values for 4BA was 0.94 M, 1PA was 1.19 M, 4BSA was 0.73 M, and NUU was 1.23 M ( Figure 6 ). When we compare these values to what was observed in our initial in vitro assays, we see that similar concentrations of compound are required to obtain inhibition of infectious particles in cell culture and CLP assembly in vitro.
We see 0 Figure 6 and Supplementary Figure 1 ). The largest difference between in vivo and in vitro studies was an approximately 4-fold difference for NNU.
The EC50 observed by our study (Figure 6 ) indicate that four compounds are promising leads.
Several groups have studied the antiviral properties of dioxane and its derivatives which bind in the hydrophobic pocket of capsid protein and subsequently interfere with the capsid-E2
interaction (17) (18) (19) . Like Sharma et al. saw with CHIKV and picolic, we observed the best inhibition when 4BSA and virus were added simultaneously. However, they reported that 2 mM of picolic acid was needed to inhibit infectious virus production by 50-60% (19); in contrast, <2 M of the four compounds identified by our study was needed to reduce infectious virus production by 50%.
Core assembly is targeted by compound 4BSA
The four compounds that we focused on reduced the number of infectious particles released during a virus infection. Their effectiveness depends on the time of their addition, and their EC50 values range from 0.7-1.25 M. Our initial screen looked at modulators of core assembly. Our best inhibitor, based on dose response and inhibition of infectious virus, was 4BSA. To determine if 4BSA inhibited core assembly in CHIKV-infected cells, we examined lysate from infected cells with and without compound via centrifugation through a sucrose gradient (65) . Viral genomes are present in both infectious and non-infectious particles. To determine if the total amount of particles released was altered in the presence of these compound, we determined the genome copies in released CHIKV. CHIKV was added to cells and after adsorption, compound was added, similar to Figure 5B . After 24 hours, media was collected and assayed by qRT-PCR ( Figure 6 ). All four compounds affected the yield of total particles by less than onelog though infectious particles decreased by more than 1-log. These results suggest that viral genome are packaged in the presence of compound but the genome is not able to infect new cells.
Conclusions
In summary, we used a novel FRET-based assay to screen 10,000 compounds for their ability to inhibit or promote assembly of core-like particles. Of the initial 106 hits, eight compounds were further assessed due to their potent in vitro dose response and their lack of cellular toxicity.
From this group, we identified four compounds that could reduce production of infectious virus by at least 1-log and at least one of these compounds interferes with nucleocapsid core assembly in vivo. These results indicate that compounds with the ability to modulate core-like particle assembly also have potent antiviral activity. Our work adds to the growing body of evidence that suggest that targeting the capsid protein is an effective strategy to find new antivirals.
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Figure Legends
Modulators of CLP assembly
Dose response of compounds that increase fluorescence were tested at 320 mM NaCl and dose response of compounds that decrease were tested at 570 mM. The twelve compounds shown here were selected to be further tested in tissue culture assays using intact CHIK virus. 
